InvestorsHub Logo
Followers 0
Posts 405
Boards Moderated 0
Alias Born 02/26/2017

Re: None

Wednesday, 03/29/2017 7:31:56 PM

Wednesday, March 29, 2017 7:31:56 PM

Post# of 106839
Considering the below facts are true coupled with a untapped multi billion market opportunity (side note: Look up Flexogenix regenerative medicine. That company makes millions doing similar stuff; cash pay model and each office cost $1M to build out) how can you even argue it won't go to the moon. They climbed out from under a big number and now cash flow positive. WOW!

Financial highlights from 2016 include:
Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M, or 23.8%, from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company's history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015